Skip to main content
Premium Trial:

Request an Annual Quote

Glycotest, Oncimmune Explore Combining Technologies for Liver Cancer

NEW YORK (GenomeWeb) – NetScientific today announced that its portfolio firm Glycotest is collaborating with Oncimmune to investigate combining their technologies for the early detection of liver cancer.

Glycotest and Oncimmune will jointly clinically validate their combined tests, which could then be co-developed.

Oncimmune is contributing its autoantibody-based lung cancer test, EarlyCDT-Lung, to the collaboration. The Rockville, Md.-based biotech firm is expanding the technology to detect liver cancer and other solid tumor cancers. Glycotest, a spinout of Drexel University College of Medicine and Baruch S. Blumberg Institute, is developing proprietary glycoprotein biomarkers and assay technology for liver diseases, including liver cancer.

"We believe that the most clinically valid and cost-effective way to address the early detection of cancer is via two routes, through the further development of our proprietary autoantibody technology and its combination with other complementary technologies," Oncimmune CEO Geoffrey Hamilton-Fairley said in a statement.

Financial and other terms of the agreement were not disclosed.

NetScientific is a biomedical and healthcare technology group that funds and develops technologies.